Welcome to our dedicated page for KYNTRA BIO news (Ticker: KYNB), a resource for investors and traders seeking the latest updates and insights on KYNTRA BIO stock.
Kyntra Bio reports news around its oncology and rare disease development programs, financial results, and public-company updates. Recurring items include clinical updates for FG-3246 in metastatic castration-resistant prostate cancer, roxadustat development for anemia associated with lower-risk myelodysplastic syndromes, and work involving the FG-3180 CD46-targeted PET biomarker.
Company announcements also cover quarterly and annual results, business updates, medical and investor conference presentations, and corporate matters related to its Nasdaq-listed common stock and former FibroGen identity.
Kyntra Bio (Nasdaq: KYNB) announced management will participate in investor conferences in February–March 2026. Presentations: Oppenheimer 36th Annual Healthcare Life Sciences (virtual, Feb 26, 2026, 2:40–3:10 PM ET) and Leerink Global Healthcare Conference (Miami, Mar 11, 2026, 2:20–2:50 PM ET).
Management will be available for one-on-one meetings; webcasts are provided and presentation replays will be posted on the company's Events & Presentations investor page for 90 days.